Correlation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximab

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 7, 2012, Pages 1081-1087

  Iwata, Daiju ^a   Namba, Kenichi ^a   Mizuuchi, Kazuomi ^a   Kitaichi, Nobuyoshi ^a,b   Kase, Satoru ^a   Takemoto, Yuko ^a   Ohno, Shigeaki ^a   Ishida, Susumu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Anti TNF monoclonal antibody; Antinuclear antibody; Beh et's disease; Biomarker; Infliximab; Retinal vasculitis; Uveitis

Indexed keywords

ANTINUCLEAR ANTIBODY; DOUBLE STRANDED DNA ANTIBODY; INFLIXIMAB; PREDNISOLONE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; JAPANESE; LABORATORY TEST; LUPUS LIKE SYNDROME; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RELAPSE; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; BEHCET SYNDROME; CHILD; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ACUITY;

EID: 84864281987     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-011-1908-1     Document Type: Article

References (51)

1. Kitamei H, Kitaichi N, Namba K, Kotake S, Goda C, Kitamura M, Miyazaki A, Ohno S (2009) Clinical features of intraocular inflammation in Hokkaido, Japan. Acta Ophthalmol 87:424-428
2. Kitaichi N, Miyazaki A, Iwata D, Ohno S, Stanford MR, Chams H (2007) Ocular features of Behçet's disease: an international collaborative study. Br J Ophthalmol 91:1579-1582
3. Kitaichi N, Miyazaki A, Stanford MR, Iwata D, Chams H, Ohno S (2009) Low prevalence of juvenile-onset Behçet's disease with uveitis in East/South Asian people. Br J Ophthalmol 93:1428-1430
4. Kaklamani V, Vaiopoulos G, Kaklamanis P (1998) Behçet's disease. Semin Arthritis Rheum 27:197-217
5. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behçet's disease. N Engl J Med 341:1284-1291
6. Zouboulis C (1999) Epidemiology of Adamantiades-Behçet's disease. Ann Med Interne (Paris) 150:488-498
7. Knight D, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore M, Vilcek J, Daddona P (1993) Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453
8. Elliott M, Maini R, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody J (1994) Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344:1125-1127
9. Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932-1939
10. Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J, Rachmilewitz D, Wolf D, Olson A, Bao W, Rutgeerts P, Group AIS (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359:1541-1549
11. Zhang Z, Schmitt J, Wozel G, Kirch W (2009) Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin (Munich) 104:125-136
12. Nestle F, Kaplan D, Barker J (2009) Psoriasis. N Engl J Med 361:496-509
13. Sfikakis P, Theodossiadis P, Katsiari C, Kaklamanis P, Markomichelakis N (2001) Effect of infliximab on sightthreatening panuveitis in Behçet's disease. Lancet 358:295-296
14. Muñoz-Fernández S, Hidalgo V, Fernández-Melón J, Schlincker A, Martín-Mola E (2001) Effect of infliximab on threatening panuveitis in Behçet's disease. Lancet 358:1644
15. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362-1368
16. Sfikakis P, Kaklamanis P, Elezoglou A, Katsilambros N, Theodossiadis P, Papaefthimiou S, Markomichelakis N (2004) Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 140:404-406
17. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, Gül A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 52:2478-2484
18. Accorinti M, Pirraglia M, Paroli M, Priori R, Conti F, Pivetti-Pezzi P (2007) Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Jpn J Ophthalmol 51:191-196
19. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology (Oxford) 46:1161-1164
20. Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M (2008) Safety and efficacy of infliximab therapy in active Behçet's uveitis: an open-label trial. Rheumatol Int 29:53-57
21. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M (2010) Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol 94:284-288
22. Elezoglou A, Kafasi N, Kaklamanis PH, Theodossiadis PG, Kapsimali V, Choremi E, Vaiopoulos G, Sfikakis PP (2007) Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. Clin Exp Rheumatol 25:S65-S69
23. Mizushima Y (1988) Recent research into Behçet's disease in Japan. Int J Tissue React 10:59-65
24. Jabs DA, Nussenblatt RB, Rosenbaum JT, Group SoUNSW (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140:509-516
25. Fritzler MJ, Pauls JD, Kinsella TD, Bowen TJ (1985) Antinuclear, anticytoplasmic, and anti-Sjögren's syndrome antigen A (SS-A/Ro) antibodies in female blood donors. Clin Immunol Immunopathol 36:120-128
26. de Vlam K, De Keyser F, Verbruggen G, Vandenbossche M, Vanneuville B, D'Haese D, Veys EM (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393-397
27. Forslid J, Heigl Z, Jonsson J, Scheynius A (1994) The prevalence of antinuclear antibodies in healthy young persons and adults, comparing rat liver tissue sections with HEp-2 cells as antigen substrate. Clin Exp Rheumatol 12:137-141
28. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, Gordon T, Hardin JA, Kalden JR, Lahita RG, Maini RN, McDougal JS, Rothfield NF, Smeenk RJ, Takasaki Y, Wiik A, Wilson MR, Koziol JA (1997) Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40:1601-1611
29. Fernandez SA, Lobo AZ, Oliveira ZN, Fukumori LM, AM Prigo, Rivitti EA (2003) Prevalence of antinuclear autoantibodies in the serum of normal blood donors. Rev Hosp Clin Fac Med Sao Paulo 58:315-319
30. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, Tomita Y, Muro Y (2004) Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 50:892-900
31. Al Jabri AA, Al Buloshi MS (2004) Anticardiolipin and antinuclear antibodies in the adult healthy Omani individuals. Saudi Med J 25:313-317
32. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, Veys EM, De Keyser F (2003) Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 48:1015-1023
33. Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D (2005) Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. Autoimmunity 38:155-160
34. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S (2005) Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 64:403-407
35. Pink AE, Fonia A, Allen MH, Smith CH, Barker JN (2010) Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: a retrospective, observational study. Br J Dermatol 162:780-785
36. Nancey S, Blanvillain E, Parmentier B, Flourié B, Bayet C, Bienvenu J, Fabien N (2005) Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 11:986-991
37. Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, Wain M, Barker JN (2006) Infliximab for severe, treatmentresistant psoriasis: a prospective, open-label study. Br J Dermatol 155:160-169
38. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43:2383-2390
39. Cairns AP, Duncan MK, Hinder AE, Taggart AJ (2002) New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 61:1031-1032
40. Debandt M, Vittecoq O, Descamps V, Le Loët X, Meyer O (2003) Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 22:56-61
41. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C (2002) Druginduced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 11:753-755
42. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903-912
43. Osada A, Nakashima H, Furue M, Tamaki K (1995) Up-regulation of CD44 expression by tumor necrosis factor-alpha is neutralized by interleukin-10 in Langerhans cells. J Invest Dermatol 105:124-127
44. Hart SP, Dougherty GJ, Haslett C, Dransfield I (1997) CD44 regulates phagocytosis of apoptotic neutrophil granulocytes, but not apoptotic lymphocytes, by human macrophages. J Immunol 159:919-925
45. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR (1998) Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41:1241-1250
46. Cairns AP, Crockard AD, McConnell JR, Courtney PA, Bell AL (2001) Reduced expression of CD44 on monocytes and neutrophils in systemic lupus erythematosus: relations with apoptotic neutrophils and disease activity. Ann Rheum Dis 60:950-955
47. Finckh A, Dudler J,Wermelinger F, Ciurea A, Kyburz D, Gabay C, Bas S, SCQM PO (2010) Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine 77:313-318
48. Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y (2010) Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 16:1898-1904
49. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, investigators Es (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367-1374
50. Adişen E, Aral A, Aybay C, Gürer MA (2010) Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study. J Dermatol 37:708-713
51. Sugita S, Yamada Y, Mochizuki M (2010) Relationship between serum infliximab levels and acute uveitis attacks in patients with Behçet disease. Br J Ophthalmol 95:549-552